Vaxcyte won its phase 3. Now it has to win the market

The technology

Vaxcyte makes pneumococcal conjugate vaccines on a cell-free protein synthesis platform, XpressCF, licensed from Sutro Biopharma. Conjugate vaccines link bacterial sugars to a carrier protein. Adding more serotypes usually means more carrier protein, which can weaken the immune response to each one. Vaxcyte says its site-specific, carrier-sparing method lets it pack in more serotypes without that loss.

OPUS-1 was the test. VAX-31 met all prespecified primary endpoints against Pfizer's Prevnar 20 and Merck's Capvaxive in 4,047 adults. The flaw: against Capvaxive alone, serotypes 3 and 12F missed the stricter 0.667 noninferiority bar and met only the historical 0.5 bar.

The odds

The largest clinical risk is behind the company. Two descriptive adult phase 3 trials, OPUS-2 and OPUS-3, report in the first half of 2027, followed by a manufacturing consistency study and a BLA in the first half of 2028. Historically 90.6% of filed applications are approved across all diseases, and the safety data so far showed no vaccine-related serious adverse events.

The harder question is the label and recommendations. Chief scientific officer James Wassil said the company expects the comparison with Capvaxive to be a particular focus of FDA review, because Capvaxive's unique serotypes cause more adult disease in the U.S. today. How vaccine advisers treat serotypes 3 and 12F will shape uptake.

The money

Vaxcyte had $2,507.7 million in cash, cash equivalents and investments at June 30, 2026, then raised about $544.3 million in equity and $558.7 million in convertible notes in October. It used $513.1 million in operating cash in the first half and is paying for dedicated manufacturing at Lonza in Switzerland. It has no product revenue.

The risks

The main risk is commercial. Vaxcyte says the market is $8.5 billion and could reach about $12 billion by 2030, but it will enter against Pfizer and Merck, two of the three companies behind those reported sales. A BLA in 2028 means any launch is at least two years away.

Manufacturing is the second risk. A 31-valent vaccine is complex to make at scale, and Vaxcyte depends on Lonza for important components. The new convertible notes add $575 million of debt due in 2032 if not converted.

Our read

Vaxcyte did what it needed to in OPUS-1, and the platform claim now has phase 3 support. It also raised money at a good moment. The company's value now depends on execution over a long runway: two more phase 3 readouts, a manufacturing study, a filing in 2028, and then a fight for recommendations against two of the largest vaccine makers. The serotype 3 and 12F results are the one clinical detail that could cost it share in that fight.

There is also a structural point in Vaxcyte's favor. Pneumococcal vaccines compete largely on breadth of coverage, and the company says VAX-31 could add coverage of 13% to 36% of invasive pneumococcal disease and 19% to 31% of pneumococcal pneumonia over current adult vaccines. If regulators and advisers accept that breadth as worth more than a small shortfall on two serotypes, the product has a clear selling point. If they weigh the two serotypes heavily, Vaxcyte may face a narrower recommendation. The new leadership hires, including a chief medical officer who worked on Prevnar 13 and Prevnar 20 at Pfizer, suggest the company knows where that argument will be won. The infant program, with phase 2 data due by the end of the first half of 2027, is the other source of upside, aimed at a pediatric market the company describes as large, well-established and highly durable.